Patents by Inventor Robert A. Baughman

Robert A. Baughman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11304992
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: April 19, 2022
    Assignee: MANNKIND CORPORATION
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Publication number: 20210361746
    Abstract: An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.
    Type: Application
    Filed: August 3, 2021
    Publication date: November 25, 2021
    Applicant: MannKind Corporation
    Inventors: Marshall Grant, Simon R. Bruce, Robert A. Baughman
  • Patent number: 11110151
    Abstract: An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: September 7, 2021
    Assignee: MannKind Corporation
    Inventors: Marshall Grant, Simon R. Bruce, Robert A. Baughman
  • Publication number: 20210138040
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 13, 2021
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Patent number: 10857207
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 8, 2020
    Assignee: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Publication number: 20200146981
    Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.
    Type: Application
    Filed: January 13, 2020
    Publication date: May 14, 2020
    Inventors: Peter Richardson, Robert A. Baughman, Andrea Leone-Bay, Donald Costello
  • Publication number: 20200147180
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 14, 2020
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Publication number: 20200147219
    Abstract: A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.
    Type: Application
    Filed: January 14, 2020
    Publication date: May 14, 2020
    Inventors: Peter Richardson, Robert A. Baughman, Donald Costello
  • Publication number: 20190365866
    Abstract: An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.
    Type: Application
    Filed: June 21, 2019
    Publication date: December 5, 2019
    Applicant: MannKind Corporation
    Inventors: Marshall Grant, Simon R. Bruce, Robert A. Baughman
  • Publication number: 20190167580
    Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Inventors: Peter Richardson, Robert A. Baughman, Andrea Leone-Bay, Donald Costello
  • Publication number: 20180185453
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: March 2, 2018
    Publication date: July 5, 2018
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Patent number: 9943571
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: April 17, 2018
    Assignee: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Publication number: 20170304404
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: July 3, 2017
    Publication date: October 26, 2017
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Publication number: 20150283213
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: May 22, 2015
    Publication date: October 8, 2015
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Patent number: 9078866
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with Type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: July 14, 2015
    Assignee: MannKind Corporation
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Publication number: 20150080298
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 19, 2015
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Patent number: 8921311
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: December 30, 2014
    Assignee: MannKind Corporation
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Publication number: 20140100158
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: December 10, 2013
    Publication date: April 10, 2014
    Applicant: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Patent number: 8623817
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: January 7, 2014
    Assignee: Mannkind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Publication number: 20130125886
    Abstract: A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.
    Type: Application
    Filed: January 2, 2013
    Publication date: May 23, 2013
    Inventors: Peter Richardson, Robert A. Baughman, Donald Costello